Drug Profile
Research programme: stress protein immunomodulation therapy - Stressgen
Alternative Names: Stress protein allergy therapy - Stressgen; Stress protein asthma therapy - StressgenLatest Information Update: 09 Oct 2002
Price :
$50
*
At a glance
- Originator Nventa Biopharmaceuticals Corporation
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Hypersensitivity
Most Recent Events
- 09 Oct 2002 Discontinued - Preclinical for Allergy in USA (unspecified route)
- 09 Oct 2002 Discontinued - Preclinical for Asthma in USA (unspecified route)
- 06 Oct 1999 New profile